In preparation for its upcoming launch of a Phase 1b clinical trial, WHV engaged a well-known expert Dr. Mireya Wesselossky as our Medical Officer.
To follow up on the HVTN 124 phase 1 clinical trial, WHV is preparing to launch a phase 1b clinical trial WHV138 to further explore the safety and immunogenicity of its polyvalent PDPHV vaccine candidate. Different administration approaches and schedules will be explored in that study and the company is preparing to file an IND with the US FDA in the near future. As a Medical Officer, Dr. Wesselossky will join the Protocol Leadership team and will oversee the regular safety reports in WHV 138.
Dr. Wesselossky has been Associate Professor of Medicine at University of Massachusetts Medical School and an Infectious Disease Attending Physician at UMass Memorial Health Care since 2001. She has extensive experience with HIV, previously working with a >700 HIV-infected patients in the HIV Associated Neurocognitive Disorders (HAND) cohort in Central Massachusetts. In January 2018, she participated in opening a walk-in clinic in AIDS Project Worcester to diagnose, treat, and prevent many infectious disease conditions including sexual transmitted diseases, HIV, and HCV in a population with no easy access to medical care due to extreme poor socio-economic status.
Dr Wesselossky’s experience and unique strengths as an infectious diseases clinician and researcher will be invaluable for the conduct of the WHV 138 trial.
